Fig. 8.
Schematic illustration of this study: the findings of E2-induced PRLoma were typically observed with the 13-wk treatment in the E2 group in this study and the inhibitory effect were observed in the E2+G6-31 group with simultaneous use of G6-31 (Anti-VEGF-A antibody) for the last 3 wks of the E2 treatment period.